Bevacizumab biosimilar(Mycenax Biotech)

贝伐珠单抗生物类似药（永昕生物）

Report date: 2022/03/16 13:19:31

Base Information

Drug NameBevacizumab biosimilar(Mycenax Biotech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMycenax Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesMycenax Biotech Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A